Clinical trials: Transmission
Hiv
Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi
There is promising evidence that couple-based approaches within Malawi's Option B+ prevention of mother to child transmission program could address help address 1) poor male engagement in the HIV continuum of care, 2) low male…
- Trial name
- NCT03477279
- Testing
- Enhanced Couple HIV Testing and Counseling
- Where
- Malawi
- Volunteers
- 1,116 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV/AIDS, Cancer
Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer
This is a one year study to develop and test a culturally-tailored, web-based cognitive behavioral stress management (CBSM) intervention for Latino sexual minority men living with both HIV and cancer.
- Trial name
- C-SmartManage (NCT03993054)
- Testing
- Culturally-tailored cognitive behavioral stress management
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Miami
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
HIV, Buprenorphine, and the Criminal Justice System
The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design.
- Conditions
- Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
- Trial name
- STRIDE (NCT01550341)
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Tuberculosis, Latent Tuberculosis
Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)
The Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial) study will be a three-arm, open-label, parallel, randomized trial.
- Conditions
- Tuberculosis, Latent Tuberculosis, HIV/AIDS
- Trial name
- NCT03934931
- Testing
- Streamlined weekly DOT visits, Weekly DOT visit reminders, Cost reimbursement DOT
- Where
- Uganda
- Volunteers
- 1,656 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV Infection
An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)
Approximately 100 HIV-uninfected YMSM at high risk of acquiring HIV infection, between the ages of 15 and 17 inclusive will be enrolled across all participating Adolescent Medicine Trial Units (AMTUs).
- Trial name
- NCT01769456
- Testing
- PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
- Where
- 6 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV, Acquired Immunodeficiency Syndrome
A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk
The intent of the proposed randomized controlled trial is to test the efficacy of a principle-based, transdiagnostic cognitive behavioral therapy (CBT) intervention that addresses the pathways through which minority stress…
- Trial name
- NCT02929069
- Testing
- ESTEEM, CMHT, VCT
- Where
- 2 sites in United States
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV Infections, Opioid-Related Disorders
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries.
- Trial name
- NCT00270257
- Testing
- Buprenorphine/Naloxone
- Where
- 4 sites in China, Thailand
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences
While the numbers of HIV infected veterans under the age of 50 are declining, the percentage of HIV infected veterans over the age of 50 is increasing with the largest percentage increases in the 50-59 age group and the 70+ age…
- Trial name
- NCT00675766
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
HIV Infections, Sexually Transmitted Diseases
Mesalamine to Reduce T Cell Activation in HIV Infection
The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected patients, possibly resulting in better…
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections
- Trial name
- NCT01090102
- Testing
- Mesalamine (5-aminosalicylic acid, Apriso)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Francisco
Syphilis
Lumbar Puncture and Syphilis Outcome
Treponema pallidum, the bacterium that causes syphilis, invades the central nervous system in about 40% of patients with syphilis. This happens early after infection.
- Trial name
- NCT02031146
- Testing
- Lumbar puncture
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- University of Washington
Hiv
Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection
This study evaluates whether a 7-day course of Raltegravir 400mg bd or Raltegravir 400mg/lamivudine 150mg bd can prevent HIV from infecting genital tissue and will relate the level of drug in the blood to the level of drug in…
- Trial name
- R-PrEP (NCT03205566)
- Testing
- Raltegravir 400Mg Tab, Lamivudine 150Mg Tablet
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
HIV Infections
A Gender-Enhanced Pre-Exposure Prophylaxis (PrEP) Information-Motivational Workshop for Young South African Women
This is a phase 1 pilot study to assess feasibility and acceptability and potential for impact of a gender-enhanced virtual group workshop focused on oral Pre-Exposure Prophylaxis (PrEP) as an HIV prevention method for young…
- Trial name
- Masibambane (NCT04833127)
- Testing
- Gender-Enhanced -- Masibambane, Individually accessed
- Where
- South Africa
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
HIV
HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
This study will recruit men and transgender women with acute or recent HIV infection. It wil look at how HIV medicines (ART) when given very early after HIV infection affect the amount of HIV in the blood, semen and rectal…
- Trial name
- SABES? (NCT01815580)
- Testing
- Atripla or Stribild
- Where
- Peru
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
The purpose of this study is to determine the safety and effectiveness of an anti-HIV drug regimen followed by treatment interruption in people recently infected with HIV.
- Trial name
- NCT00414518
- Testing
- Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
- Where
- 3 sites in United States, Zimbabwe
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
HIV Infections
Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
This study will examine whether interleukin-2 (IL-2) given before the interruption of antiretroviral (ARV) treatment could significantly extend the period of time that a patient is temporarily not taking ARV treatment and also…
- Trial name
- ILIADE (NCT00071890)
- Testing
- Interleukin 2, HAART, Treatment interruption
- Where
- 2 sites in United States, France
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A phase 1/2a clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants
- Trial name
- HVTN 120 (NCT03122223)
- Testing
- ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B)
- Where
- 12 sites in United States, Tanzania and 2 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
Infection with HIV-1 continues to be a serious health threat throughout the world. Chronic exposure to combination anti-retroviral therapy identified anti-retroviral associated long-term toxicities.
- Trial name
- NCT03784079
- Testing
- GSK3640254
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 34 people
- Sponsor
- ViiV Healthcare
Trichuriasis, Ascariasis
Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
This study is a double-blind randomized controlled superiority trial aiming at providing evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to albendazole monotherapy in school-aged…
- Conditions
- Trichuriasis, Ascariasis, Hookworm Infections
- Trial name
- Moxiped (NCT06188715)
- Testing
- Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet
- Where
- Tanzania
- Volunteers
- 224 people
- Sponsor
- Jennifer Keiser
Human Papillomavirus Infection
Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)
This is a post-licensure safety surveillance program to detect potential safety signals in subjects, from the managed care organizations database, who have used GARDASIL™.
- Trial name
- NCT01078220
- Volunteers
- 189,629 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
1. Hypothesis: If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer worldwide, the genotypes associated with cervical cancer in Venezuela would be the same types found in other countries. 2.
- Trial name
- HPI (NCT00937547)
- Where
- 2 sites in Venezuela
- Volunteers
- 329 people
- Sponsor
- Instituto Oncologico Luis Razetti
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.